ABSTRACT
Background Severe exacerbations requiring hospitalization are an important component of the natural history of asthma and a major source of its burden. Whether the occurrence of a severe exacerbation affects the rate of subsequent events has far-reaching implications in asthma management.
Methods Using the centralized administrative health databases of British Columbia, Canada (1997/01/01 –2016/03/31), we created an incidence cohort of patients with at least one severe asthma exacerbation, defined as an episode of hospitalization with asthma as the primary diagnosis. We used an accelerated failure time joint frailty model for the time intervals between severe asthma exacerbations. Analyses were conducted separately for pediatric (< 14 years old) and adult (≥14 years old) patients.
Results There were 3,039 patients (mean age at baseline 6.4, 35% female) in the pediatric group and 5,459 patients (mean age at baseline 50.8, 68% female) in the adult group, with 16% and 15%, respectively, experiencing at least one severe asthma exacerbation during follow-up. The first follow-up severe asthma exacerbation was associated with an increase of 79% (95% CI: 15% – 186%) in the rate of the subsequent events for the pediatric group. The corresponding value was 186% (95% CI: 85% – 355%) for the adult group. For both groups, the effects of subsequent severe exacerbations were not statistically significant.
Conclusion Our findings suggest that among patients who have experienced their first severe asthma exacerbation, preventing the next event can drastically change the course of the disease and reduce the burden of future exacerbations.
Competing Interest Statement
T.Y.L reports no conflict of interest. J.P. reports personal fees from Biogen, personal fees from Teva Pharmaceuticals Europe, personal fees from The Canadian Study Group on CCSVI, personal fees from Novartis, grants from Natural Sciences and Engineering Research Council of Canada (NSERC), outside the submitted work. M.S. has received honoraria from GlaxoSmithKline, Boehringer Ingelheim, Teva, and AstraZeneca. He has received research fund directly into his accounts at The University of British Columbia from AtraZeneca, Boehringer Ingelheim, and MethaPharm Inc.
Funding Statement
This study was funded by Genome Canada and Genome British Columbia - 274CHI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the Human Ethics Board of the University of British Columbia (H17-00938).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study are from Population Data BC. They are available to the public under restrictions, according to British Columbia's Freedom of Information and Protection of Privacy Acts.
https://www.popdata.bc.ca/privacy/policies/legislativeframework
